Restrepo Ruben D
Department of Respiratory Care, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, Mail Code 6248, San Antonio TX 78229-3900, USA.
Respir Care. 2007 Sep;52(9):1159-73; discussion 1173-5.
Pulmonary mucociliary clearance is an essential defense mechanism against bacteria and particulate matter. Mucociliary dysfunction is an important feature of obstructive lung diseases such as chronic obstructive pulmonary disease, asthma, cystic fibrosis, and bronchiectasis. This dysfunction in airway clearance is associated with accelerated loss of lung function in patients with obstructive lung disease. The involvement of the cholinergic and adrenergic neural pathways in the pathophysiology of mucus hypersecretion suggests the potential therapeutic role of bronchodilators as mucoactive agents. Although anticholinergics and adrenergic agonist bronchodilators have been routinely used, alone or in combination, to enhance mucociliary clearance in patients with obstructive lung disease, the existing evidence does not consistently show clinical effectiveness.
肺黏液纤毛清除是抵御细菌和颗粒物的重要防御机制。黏液纤毛功能障碍是慢性阻塞性肺疾病、哮喘、囊性纤维化和支气管扩张等阻塞性肺疾病的一个重要特征。气道清除功能的这种障碍与阻塞性肺疾病患者肺功能的加速丧失有关。胆碱能和肾上腺素能神经通路参与黏液分泌过多的病理生理学过程,提示支气管扩张剂作为黏液活性药物具有潜在的治疗作用。尽管抗胆碱能药物和肾上腺素能激动剂支气管扩张剂已常规单独或联合使用,以增强阻塞性肺疾病患者的黏液纤毛清除功能,但现有证据并未一致显示其临床疗效。